RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunoprecise Antibodies Stock

Immunoprecise Antibodies Stocks 2024

Immunoprecise Antibodies Stocks

24.9 M

Ticker

IPA

ISIN

CA45257F2008

WKN

A2QJEC

In 2024, Immunoprecise Antibodies had 24.9 M outstanding stocks, a 0% change from the 24.9 M stocks in the previous year.

The Immunoprecise Antibodies Stocks history

YEARNUMBER OF STOCKS (undefined CAD)
2030e24.9
2029e24.9
2028e24.9
2027e24.9
2026e24.9
2025e24.9
2024e24.9
202324.9
202219.69
202116.47
202013.63
201912.54
20189.11
20173.96
20150.55
20140.55
20130.55
20120.55
20110.55
20100.55
20090.55
20080.48
20070.41
20060.38
20050.34
20040.29
20030.24

Immunoprecise Antibodies shares outstanding

The number of shares was Immunoprecise Antibodies in 2023 — This indicates how many shares 24.897 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immunoprecise Antibodies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immunoprecise Antibodies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immunoprecise Antibodies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immunoprecise Antibodies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immunoprecise Antibodies Aktienanalyse

What does Immunoprecise Antibodies do?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Immunoprecise Antibodies's Shares Outstanding

Immunoprecise Antibodies's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Immunoprecise Antibodies’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Immunoprecise Antibodies’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Immunoprecise Antibodies’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Immunoprecise Antibodies stock

How many stocks are there of Immunoprecise Antibodies?

The current number of stocks of Immunoprecise Antibodies is 24.9 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Immunoprecise Antibodies are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Immunoprecise Antibodies evolved in recent years?

The number of shares of Immunoprecise Antibodies has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Immunoprecise Antibodies as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Immunoprecise Antibodies?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Immunoprecise Antibodies pay?

Over the past 12 months, Immunoprecise Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunoprecise Antibodies is expected to pay a dividend of 0 CAD.

What is the dividend yield of Immunoprecise Antibodies?

The current dividend yield of Immunoprecise Antibodies is .

When does Immunoprecise Antibodies pay dividends?

Immunoprecise Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunoprecise Antibodies?

Immunoprecise Antibodies paid dividends every year for the past 0 years.

What is the dividend of Immunoprecise Antibodies?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunoprecise Antibodies located?

Immunoprecise Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunoprecise Antibodies from 9/27/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Immunoprecise Antibodies pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Immunoprecise Antibodies in the year 2023?

In the year 2023, Immunoprecise Antibodies distributed 0 CAD as dividends.

In which currency does Immunoprecise Antibodies pay out the dividend?

The dividends of Immunoprecise Antibodies are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunoprecise Antibodies

Our stock analysis for Immunoprecise Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunoprecise Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.